Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
AssigneesNovartis AG, The Trustees of the University of Pennsylvania
InventorsJennifer Brogdon, Carl H. June, Andreas Loew, Marcela Maus, John Scholler
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
Claims21
A method of providing an anti-tumor immunity in a mammal having a hematological cancer that is positive for CD19 comprising administering to the mammal an effective amount of a monotherapy comprising a cell expressing a chimeric antigen receptor (CAR) molecule, wherein the CAR molecule comprises a humanized anti-CD19 binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the humanized anti-CD19 binding domain comprises a light chain complementarity determining region 1 (LC CDR1) of SEQ ID NO:
- 25, a light chain complementarity determining region 2 (LC CDR2) of SEQ ID NO:
- 26, a light chain complementarity determining region 3 (LC CDR3) of SEQ ID NO:
- 27, a heavy chain complementarity determining region 1 (HC CDR1) of SEQ ID NO:
- 19, a heavy chain complementarity determining region 2 (HC CDR2) of SEQ ID NO:
- 21, 22, or 23, and a heavy chain complementarity determining region 3 (HC CDR3) of SEQ ID NO:
- 24.
A method of treating a mammal having a hematological cancer that is positive for CD19 comprising administering to the mammal an effective amount of a monotherapy comprising a cell comprising a chimeric antigen receptor (CAR) molecule, wherein the CAR molecule comprises a humanized anti-CD19 binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the humanized anti-CD19 binding domain comprises a light chain complementarity determining region 1 (LC CDR1) of SEQ ID NO:
- 25, a light chain complementarity determining region 2 (LC CDR2) of SEQ ID NO:
- 26, a light chain complementarity determining region 3 (LC CDR3) of SEQ ID NO:
- 27, a heavy chain complementarity determining region 1 (HC CDR1) of SEQ ID NO:
- 19, a heavy chain complementarity determining region 2 (HC CDR2) of SEQ ID NO:
- 21, 22, or 23, and a heavy chain complementarity determining region 3 (HC CDR3) of SEQ ID NO:
- 24.
Dependencies are inferred from the claim text.